ProPhase Labs, Inc. Announces Resignation of Mark Frank from Board
April 18, 2015 at 01:51 am IST
Share
On April 15, 2015, current Board Member Mark Frank notified ProPhase Labs, Inc. of his decision not to seek re-election to the Board. Mr. Frank's retirement from the Board will become effective as of the company's 2015 Annual Meeting of Stockholders on June 16, 2015.
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.